Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Robert W. Kulawy"'
Autor:
Jennifer M. Victory, Anne C. Hermann, Mario L. Rocci, Anne N. Nafziger, Robert W. Kulawy, Joseph S. Bertino
Publikováno v:
The Journal of Clinical Pharmacology. 45:614-619
Progesterone products are available in prescription form as well as over-the-counter (OTC) topical preparations sold for "cosmetic" uses. In a randomized study design, the authors compared the drug exposure from an OTC progesterone cream to a Food an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf4d767381adfbfb1d042ed10e6249c9
https://doi.org/10.1177/0091270005276621
https://doi.org/10.1177/0091270005276621
Autor:
Debra J. Beck, Shirley M. Tsunoda, Daniel S Streetman, Angela D. M. Kashuba, Edna F. Choo, Grant R. Wilkinson, Jooran S. Kim, Anne N. Nafziger, Robert W. Kulawy, David J. Greenblatt, Joseph S. Bertino, Mario L. Rocci
Publikováno v:
Journal of Clinical Pharmacology. 42:376-382
Midazolam clearance is used to phenotype hepatic CYP3A activity but requires multiple plasma samples following a single intravenous dose. The authors evaluated the use of a limited sampling scheme, using different assay techniques to determine the re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d78ac2d11d4d9efe0ae9ce1c2d74e620
https://doi.org/10.1177/0091270002424002
https://doi.org/10.1177/0091270002424002
Autor:
J. Steven Leeder, Debra J. Beck, Robert W. Kulawy, Russell Gotschall, Anne N. Nafziger, Joseph S. Bertino, Mario L. Rocci, Gregory L. Kearns, Angela D. M. Kashuba
Publikováno v:
Clinical Pharmacology & Therapeutics. 64:257-268
Objective To determine the effect of 150 mg/day fluvoxamine on the activities of CYP1A2, CYP2D6, CYP3A, N-acetyltransferase-2 (NAT2), and xanthine oxidase (XO) by phenotyping with caffeine, dextromethorphan, and midazolam. Methods Oral caffeine (2 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0742c486e8977ffd6b6f49ba802653e7
https://doi.org/10.1016/s0009-9236(98)90174-6
https://doi.org/10.1016/s0009-9236(98)90174-6
Autor:
Ya Chi Chen, Joseph S. Bertino, S. Karl Gotzkowsky, Robert W. Kulawy, Mario L. Rocci, Angela D. M. Kashuba, Anne N. Nafziger
Aims A non-invasive proposed method for measuring CYP3A activity is the urinary 6β-hydroxycortisol:cortisol ratio. This ratio has been used as an indicator of CYP3A induction and inhibition, with mixed results. This investigation evaluated the relat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::890a1635d00cec5e3f9b6c1a1290d229
Autor:
Jooran S, Kim, Anne N, Nafziger, Shirley M, Tsunoda, Edna E, Choo, Daniel S, Streetman, Angela D M, Kashuba, Robert W, Kulawy, Debra J, Beck, Mario L, Rocci, Grant R, Wilkinson, David J, Greenblatt, Joseph S, Bertino
Publikováno v:
Journal of clinical pharmacology. 42(4)
Midazolam clearance is used to phenotype hepatic CYP3A activity but requires multiple plasma samples following a single intravenous dose. The authors evaluated the use of a limited sampling scheme, using different assay techniques to determine the re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::039669ed867a617dd9ade8f5b5fc1cc5
https://pubmed.ncbi.nlm.nih.gov/11936561
https://pubmed.ncbi.nlm.nih.gov/11936561
Autor:
Daniel S. Streetman, Mario L. Rocci, Anne N. Nafziger, Joseph S. Bertino, Robert W. Kulawy, A. D. M. Kashuba
Publikováno v:
Pharmacogenetics. 11(4)
Midazolam (MDZ) total clearance (ClT) is widely used for cytochrome P450 3A (CYP3A) phenotyping, but requires up to eight blood samples. This study was conducted to compare the use of midazolam ClT to use of a midazolam urinary metabolic ratio for CY
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3482f5d4003b39af264b096b37614d4a
https://pubmed.ncbi.nlm.nih.gov/11434513
https://pubmed.ncbi.nlm.nih.gov/11434513
Autor:
Anne N. Nafziger, M. L. Rocci, Debra J. Beck, Joseph S. Bertino, Angela D. M. Kashuba, Robert W. Kulawy
Publikováno v:
Clinical pharmacology and therapeutics. 64(3)
Objective Intraindividual variability and the effects of sex and menstrual cycle phase on CYP3A activity were evaluated by phenotyping with use of midazolam as the probe drug. Methods Midazolam (0.025 mg/kg) was administered intravenously to 10 white
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d67df0ced022d43e8d377e3d2632062b
https://pubmed.ncbi.nlm.nih.gov/9757150
https://pubmed.ncbi.nlm.nih.gov/9757150
Autor:
Anne N. Nafziger, A. C. Hermann, Robert W. Kulawy, Joseph S. Bertino, M. L. Rocci, J. Victory
Publikováno v:
Clinical Pharmacology & Therapeutics. 75:P10
Progesterone cream is an OTC (non-prescription) product that contains USP Progesterone (P). The exposure (E) of progesterone cream (PC) was compared to an FDA approved oral micronized form of P. Twelve healthy postmenopausal (as determined by elevate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee261b784566e4a2c4732ded496c5411
https://doi.org/10.1016/j.clpt.2003.11.036
https://doi.org/10.1016/j.clpt.2003.11.036
Autor:
M. L. Rocci, Joseph S. Bertino, Russell Gotschall, Debra J. Beck, Gregory L. Kearns, J. S. Leeder, Robert W. Kulawy, Anne N. Nafziger, Angela D. M. Kashuba
Publikováno v:
Clinical Pharmacology & Therapeutics. 65:170-170
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdf85c6ff256f07bbbae31c11e16d5f2
https://doi.org/10.1016/s0009-9236(99)80213-6
https://doi.org/10.1016/s0009-9236(99)80213-6